l-Carnitine ameliorates the osteoporotic changes and protects against simvastatin induced myotoxicity and hepatotoxicity in glucocorticoid-induced osteoporosis in rats - 18/06/22
Abstract |
The current study aimed to discover more effective drugs to treat osteoporosis (OP) with fewer side effects. OP was induced in 24 rats using dexamethasone (DEX) 7 mg/kg intramuscular once weekly for four weeks, with six rats as a negative control. The osteoporotic rats were divided into one untreated group (positive control) and three treated groups (n = 6) that received L-carnitine (L-Car) (100 mg/kg/d), simvastatin (SIMV) (10 mg/kg/d), and L-Car + SIMV in the same previous doses, all treatments were orally for four weeks. At the end of the experiment, serum calcium (Ca), phosphorous (P), alkaline phosphatase (ALP), osteoprotegerin (OPG), total antioxidant (TAO), creatine kinase (CK), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels were measured. The femur was histopathologically examined. Serum Ca, OPG, and TAO levels increased significantly, while P and ALP levels decreased in the L-Car and SIMV treated groups compared to the DEX-treated group. Moreover, there was a significant decrease in CK, ALT, and AST levels in the L-Car and L-Car + SIMV treated groups compared to the DEX treated group.
Conclusions |
L-Car and SIMV have antiosteoporotic effects, as well as a synergistic effect. Moreover, L-Car ameliorates SIMV-induced myotoxicity and hepatoxicity.
Le texte complet de cet article est disponible en PDF.Highlights |
• | L-Carnitine and simvastatin have an antiosteoporotic effect. |
• | L-Carnitine and simvastatin produce an antiosteoporotic effect via antioxidant and induction of osteoprotegerin protein. |
• | There is a synergistic effect between l-carnitine and simvastatin. |
• | Simvastatin induces myotoxicity and hepatotoxicity. |
• | L-Carnitine reduces the elevated creatine kinase, ALT, and AST caused by simvastatin. |
Keywords : Hepatotoxicity, l-carnitine, Myotoxicity, Osteoporosis, Simvastatin
Abbreviations : OP, L-Car, SMVA, DEX, CK, ALP, OPG
Plan
Vol 152
Article 113221- août 2022 Retour au numéro
Article précédent
- SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice
- Qiaoyun Gong, Rulin Zhang, Fang Wei, Junwei Fang, Jingfa Zhang, Jun Sun, Qian Sun, Haiyan Wang
- A011, a novel small-molecule ligand of σ2 receptor, potently suppresses breast cancer progression via endoplasmic reticulum stress and autophagy
- Yuyun Li, Xiaoyang Xie, Shiyi Liao, Zhanwei Zeng, Siyan Li, Baocheng Xie, Qunfa Huang, Huan Zhou, Chenhui Zhou, Jiantao Lin, Yunsheng Huang, Daohua Xu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?